Efficacy and Safety of Jianpi Jieyu Decoction for Patients with Mild-to-Moderate Depression of Xin (Heart)-Pi (Spleen) Deficiency Syndrome: A Multi-centre Randomized Controlled Study

CHEN Xu; CHEN Jiu-xi; HAN Xue-yan; ZHAO Yang; CAO Jing; JIAO Xiu-zhen; LIU Hong-mei; GUO Chun-li; MENG Shuo; LIANG Shuai; QI Jiang-xia; CHEN Dong; LI Ming-xia; JIAO Yun-xia; WANG Ting-ting; HONG Xia

doi:10.1007/s11655-022-3685-6

Your Location：

Home >

Browse articles >

Efficacy and Safety of Jianpi Jieyu Decoction for Patients with Mild-to-Moderate Depression of Xin (Heart)-Pi (Spleen) Deficiency Syndrome: A Multi-centre Randomized Controlled Study

Original Article | Updated：2023-04-05

- Efficacy and Safety of Jianpi Jieyu Decoction for Patients with Mild-to-Moderate Depression of Xin (Heart)-Pi (Spleen) Deficiency Syndrome: A Multi-centre Randomized Controlled Study
- Chinese Journal of Integrative Medicine Vol. 29, Issue 4, Pages: 299-307(2023)
- Affiliations：
  
  1.Xiyuan Clinical Medical College, Beijing University of Chinese Medicine, Beijing (100091), China
  2.Department of Encephalopathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
  3.First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan (250355), China
  4.Institute of Clinical Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
  5.Department of Encephalopathy, Botou Traditional Chinese Medicine Hospital of Hebei Province, Botou (062150), China
  6.Institute of Basic Medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
  7.Department of Nephrology, Pinggu Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing (101299), China
- Author bio：
  
  Prof. HONG Xia, E-mail: 970236538@qq.com
- Funds：
- DOI：10.1007/s11655-022-3685-6
  CLC：
- Published：2023-04，
  
  Published Online：27 October 2022，
  
  Accepted：24 August 2022
Scan for full text
CHEN Xu, CHEN Jiu-xi, HAN Xue-yan, et al. Efficacy and Safety of Jianpi Jieyu Decoction for Patients with Mild-to-Moderate Depression of Xin (Heart)-Pi (Spleen) Deficiency Syndrome: A Multi-centre Randomized Controlled Study. [J]. Chinese Journal of Integrative Medicine 29(4):299-307(2023)
DOI：

CHEN Xu, CHEN Jiu-xi, HAN Xue-yan, et al. Efficacy and Safety of Jianpi Jieyu Decoction for Patients with Mild-to-Moderate Depression of Xin (Heart)-Pi (Spleen) Deficiency Syndrome: A Multi-centre Randomized Controlled Study. [J]. Chinese Journal of Integrative Medicine 29(4):299-307(2023) DOI： 10.1007/s11655-022-3685-6.

摘要

目的:

评价健脾解郁汤(JJD)治疗轻中度抑郁症心脾虚证患者的疗效和安全性.

方法:

2017年12月至2019年12月

该项多中心、随机、对照研究共纳入中国中医科学院西苑医院和泊头中医院140例轻度至中度抑郁症心脾虚证患者. 采用随机数字表法将患者随机分为JJD组和帕罗西汀组

每组70例. JJD组每日给予JJD(早晚两次

每次100 mL)

帕罗西汀组给予帕罗西汀(第1周每日10 mg; 第2-6周每日20 mg)

两次口服共6周. 主要指标为汉密尔顿抑郁评分量表(HAMD-17)在第6周与基线比较的变化. 次要结果指标包括汉密尔顿焦虑量表(HAMA)评分、中医症状量表评分、临床总体印象量表(CGI)评分及治疗第6周结束时

患者HAMD-17缓解(得分降低>50%)和HAMD-17减轻(得分降低≤7分)情况

并记录研究过程中的不良事件.

结果:

从基线到第6周

JJD组和帕罗西汀组患者HAMD-17评分分别下降了10.2±4.0和9.1±4.9分(

=0.689); HAMD-17缓解率分别为45.7%和30% (

=0.128). 两组患者在第2周和第4周HAMD-17评分比较

差异有统计学意义(

=0.001

=0.014). JJD组和帕罗西汀组患者HAMA评分从基线到第6周分别下降了8.1±3.0和6.9±4.3分(

=0.905)

治疗4周两组HAMA评分比较

差异有统计学意义(

=0.037). JJD组和帕罗西汀组患者中医评分分别下降11.4±5.1和10.1±6.8分(

=0.080). JJD组的不良事件发生率明显低于帕罗西汀组(7.14% /22.86%

0.05).

结论:

与帕罗西汀比较

健脾解郁汤治疗轻中度抑郁症心脾虚证患者6周有效率未见差异

而不良事件发生率明显降低(试验注册号: ChiCTR2000040922).

Abstract

Objective:

To evaluate the efficacy and safety of Jianpi Jieyu Decoction (JJD) for treating patients with mild-to-moderate depression of Xin (Heart)-Pi (Spleen) deficiency (XPD) syndrome.

Methods:

In this multi-center

randomized

controlled study

140 patients with mild-to-moderate depression of XPD syndrome were included from Xiyuan Hospital of China Academy of Chinese Medical Sciences and Botou Hospital of Traditional Chinese Medicine from December 2017 to December 2019. They were randomly divided into JJD group and paroxetine group by using a random number table

with 70 cases in each group. The patients in the JJD group were given JJD one dose per day (twice daily at morning and evening

100 mL each time)

and the patients in the paroxetine group were given paroxetine (10 mg/d in week 1; 20 mg/d in weeks 2–6)

both orally administration for a total of 6 weeks. The primary outcome was the change of 17-item Hamilton Depression Rating Scale (HAMD-17) score at week 6 from baseline. The secondary outcomes included the Hamilton Anxiety Scale (HAMA) score

Traditional Chinese Medicine Symptom Scale (TCMSS)

and Clinlcal Global Impression (CGI) scores at the 2nd

4th

and 6th weekends of treatment

HAMD-17 response (defined as a reduction in score of >50%) and HAMD-17 remission (defined as a score of ≤7) at the end of the 6th week of treatment. Adverse events (AEs) were also recorded.

Results:

From baseline to week 6

the HAMD-17 scores decreased 10.2±4.0 and 9.1±4.9 points in the JJD and paroxetine groups

respectively (

=0.689). The HAMD-17 response occurred in 60% of patients in the JJD group and in 50% of those in the paroxetine group (

=0.292); HAMD-17 remission occurred in 45.7% and 30% of patients

respectively (

=0.128). The differences of CGI scores at the 6th week were not statistically significant (

0.05). There were significant differences in HAMD-17 scores between the two groups at 2nd and 4th week (

=0.001 and

=0.014). The HAMA scores declined 8.1±3.0 and 6.9±4.3 points from baseline to week 6 in the JJD and paroxetine groups

respectively (

=0.905 between groups). At 4th week of treatment

there was a significant difference in HAMA between the two groups (

=0.037). TCMSS decreased 11.4±5.1

and 10.1±6.8 points in the JJD and paroxetine groups

respectively (

=0.080 between groups). At the 6th week

the incidence of AEs in the JJD group was significantly lower than that in the paroxetine group (7.14%

. 22.86%

0.05).

Conclusion:

Compared with paroxetine

JJD was associated with a significantly lower incidence of AEs in patients with mild-to-moderate depression of XPD syndrome

with no difference in efficacy at 6 weeks. (Trial registration No. ChiCTR2000040922)

关键词

Keywords

depressionXin (Heart)-Pi (Spleen) deficiency syndromeChinese medicineJianpi Jieyu Decoctiondepressionefficacysafety

references

Gaspersz R, Lamers F, Beekman ATF, van Hemert AM, Schoevers RA, Penninx BWJH. The impact of depressive disorder symptoms and subtypes on 6-year incidence of somatic diseases. Psychother Psychosom 2018;87:308-310.

Cheng W, Rolls ET, Ruan TH, Feng FJ. Functional connectivities in the brain that mediate the association between depressive problems and sleep quality. JAMA Psychiatry 2018;75:1052-1061.

Aaltonen KI, Isometsä E, Sund R, Pirkola S. Risk factors for suicide in depression in Finland: first hospitalized patients followed up to 24 years. Acta Psychiatr Scand 2019;139:154-163.

Zhang XY, Chen JY, Ma NL. Depression and cardiovascular disease in elderly: current understanding. J Clin Neurosci 2018;47:1-5.

Friedrich MJ. Depression is the leading cause of disability around the world. JAMA 2017;317:1517.

Holden C. Mental health. Global survey examines impact of depression. Science 2000;288:39-40.

Lu J, Xu XF, Huang YQ, Li T, Ma C, Xu GM, et al. Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study. Lancet Psychiatry 2021;8:981-990.

Catherine JH, Ronald SD, Philip JC. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 2017;4:409-418.

Sakurai H, Uchida H, Kato M, Suzuki T, Baba H, Watanabe K, et al. Pharmacological management of depression: Japanese expert consensus. J Affective Disord 2020;266:626-632.

Seetal D, Mitchell PB, Bauer M, Yatham L, Young AH, Kennedy SH, et al. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: an international consensus statement. World J Biol Psychiatry 2018;19:330-348.

Näslund J, Hieronymus F, Emilsson JF, Lisinski A, Nilsson S, Eriksson E. Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression. Acta Psychiatr Scand 2017;136:343-351.

Le X, Zhu XQ, Amy G, Yuan F, Zhou JJ, Chen X, et al. Effectiveness of mirtazapine as add-on to paroxetine vs. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial. Psychol Med 2021;51:1166-1174.

Tang SW, Tang WH, Leonard BE. Multitarget botanical pharmacotherapy in major depression: a toxic brain hypothesis. Int Clin Psychopharmacol 2017;32:299-308.

Wu KG, Wang Y, Huang X. Meta-analysis of traditional Chinese medicine in the treatment of depression. Chin J Exp Tradit Med Formul (Chin) 2013;19:325-330.

Yu Y, Zhang G, Han T, Li J, Huang HL. A network meta-analysis of Chinese patent medicine adjuvant treatment of depression with liver stagnation and spleen deficiency. China J Chin Mater Med (Chin) 2019;44:5217-5224.

Jin WD, Xing BP, Wang HQ, Chen J, Tong ZH, Wang NX. Meta-analysis of clinical efficacy of Chaihu Shugan Powder in the treatment of depression. Chin Arch Tradit Chin Med(Chin) 2009;27:1397-1399.

Hong X, Mao LJ, Wu XM, Ning X, Liu HM, Si W, et al. Data mining analysis of Professor Zhou Shaohua's depression medical records. Shaanxi J Tradit Chin Med (Chin)2010;31:1571-1573.

Hong X, Guo CL, Ning X, Zhou SH. Research on Zhou Shaohua's core drugs for depression based on complex network. Chin J Integr Med Cardio-Cerebrovasc Dis (Chin)2017;15:93-95.

Hong X, Ning X. Zhou Shaohua's experience in treating depression from the heart. Beijing J Tradit Chin Med (Chin)2014;10:732-734.

American Psychiatric Association. Translated by Zhang D, Liu C, Zhang X, et al. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. Beijing: Peking University Press; 2015:154-155.

Tang QS. TCM syndrome diagnosis criteria and treatment plan for depression. J Beijing Univ Tradit Chin Med (Chin)2011;34:810-811.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.

Zhang MY, He YL, eds. Psychiatry scale evaluation manual. Changsha: Hunan Science and Technology Press;2015:143-148, 306-309, 421-428.

Tao YF, Zhou H, Long Y, Zhang P, Fan LY. A comparative study of Shugan-jieyu Capsule and paroxetine in the treatment of depression. Med J Chin People's Health (Chin)2012;24:2347-2348.

Hu HT. Comparison of Anshen Jieyu Decoction and paroxetine in treatment of schizophrenic depression. Jilin J Chin Med (Chin) 2015;35:794-796.

Zhao HM, Jiang H, Pang TL. Clinical study on treatment of 38 cases of depression with liver depression and phlegm obstruction with Chaigui Kaiyu Decoction. Hebei J Tradit Chin Med (Chin) 2016;38:209-211.

Bayes AJ, Parker GB. Comparison of guidelines for the treatment of unipolar depression: a focus on pharmacotherapy and neurostimulation. Acta Psychiatr Scand 2018;137:459-471.

Thom RP, Alexander JL, Baron D, Garakani A, Gross L, Pine JH, et al. Selective serotonin reuptake inhibitors: how long is long enough? J Psychiatr Pract 2021;27:361-371.

Hong X, Mao LJ, Zhou SH. Zhou Shaohua's experience in treating depression with traditional Chinese medicine. Chin J Integr Med Cardio-Cerebrovasc Dis (Chin) 2010;8:624-625.

Zhou ZY, ed. Internal medicine of traditional Chinese medicine. Beijing: China Traditional Chinese Medicine Press; 2017:373.

Sheng CX, Chen ZQ, Cui HJ, Yang AL, Wang C, Wang Z, et al. Is the Chinese medicinal formula Guipi Decoction effective as an adjunctive treatment for depression? A meta-analysis of randomized controlled trials. Chin J Integr Med 2017;23:386-395.

Guo WF, Cao XL, Sheng L, Li JX, Zhang LK, Ma YZ. Expert consensus on the diagnosis and treatment of depression with integrated traditional Chinese and Western medicine. Chin J Integr Tradit West Med (Chin) 2020;40:141-148.

Wang L, Zhang YM, Du X, Ding T, Gong WL, Liu F. Review of antidepressants in clinic and active ingredients of traditional Chinese medicine targeting 5-HT1A receptors. Biomed Pharmacother 2019;120:1-9.

Gong WX, Zhu SW, Chen CC, Yin QC, Li X, Du GH, et al. The anti-depression effect of Angelicae sinensis radix is related to the pharmacological activity of modulating the hematological anomalies. Front Pharmacol 2019;10:192.

Shen J, Zhang JJ, Deng M, Liu Y, Hu Y, Zhang L. The antidepressant effect of Angelica sinensis extracts on chronic unpredictable mild stress-induced depression is mediated via the upregulation of the bdnf signaling pathway in rats. Evid Based Complement Alternat Med 2016;2016:7434692.

Lee B, Yun HY, Shim I, Lee H, Hahm DH. Bupleurum falcatum prevents depression and anxiety-like behaviors in rats exposed to repeated restraint stress. J Microbiol Biotechnol 2012;22:422-430.

Yang LL, Shergis JL, Di YM, Zhang AL, Lu CJ, et al. Managing depression with Bupleurum chinense herbal formula: a systematic review and meta-analysis of randomized controlled trials. J Altern Complement Med 2020;26:8-24.

Lu LY, Wu D, Wang K, Tang JJ, Chen G. Beneficial effects of crocin against depression via pituitary adenylate cyclase-activating polypeptide. Biomed Res Int 2020;2020:3903125.

Ji AJ, Jia J, Xu ZC, Li Y, Wu B, Ren FM, et al. Transcriptome-guided mining of genes involved in crocin biosynthesis. Front Plant Sci 2017;8:518.

Pariante CM. Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur Neuropsychopharmacol 2017;27:554-559.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Meranzin Hydrate Improves Depression-Like Behaviors and Hypomotility via Ghrelin and Neurocircuitry

Yixin Ningshen Tablet Alleviates Comorbidity of Myocardial Infarction and Depression by Enhancing Myocardial Energy Metabolism and Increasing Availability of Monoamine Neurotransmitter

Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes: A Randomized, Double-Blind,Placebo-Controlled Multicenter Clinical Study

Effect of Interactive Dynamic Scalp Acupuncture on Post-Stroke Cognitive Function, Depression, and Anxiety:A Multicenter, Randomized, Controlled Trial

Safety of Thread Embedding Acupuncture Therapy:A Systematic Review^*

Related Author

No data

Related Institution

Institute of Traditional Chinese Medicine-Related Comorbid Depression, Nanjing University of Chinese Medicine

School of Pharmacy, Henan University of Chinese Medicine

Department of Outpatient, Xuzhou Central Hospital

Department of Obstetrics and Gynecology, Women's Hospital School of Medicine, Zhejiang University

Department of Geriatrics, Affiliated Hospital of Nanjing University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰